Cure My Disease

Don't miss your cure!

 Log in / Sign up

Insulin eye drops vs. surgery: a new hope for stubborn corneal wounds?

NCT ID NCT07561398

Disease control Sponsor: Al-Shifa Trust Eye Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether insulin eye drops can heal persistent corneal defects as well as a surgical amniotic membrane graft. 214 adults with corneal sores that haven't healed after two weeks of standard treatment will receive either insulin drops every six hours or a graft. Researchers will track how many eyes fully heal and how quickly, over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
topical insulin eye drops
What this could lead to
If it works, this could offer a simpler, less invasive treatment for stubborn corneal injuries that don't heal with standard care.
What could go wrong
This is a single-center trial with 214 participants, so results may not apply to everyone. The insulin drops must be used correctly and stored properly to be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 214 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Corneal epithelial defects for more than 2 weeks no improvement using standard treatment Exclusion Criteria: * • Systemic conditions e.g. uncontrolled Diabetes, autoimmune disorders * Recent eye surgery within last 3 months * Hereditary corneal dystrophies * Active eye infections

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Persistent corneal epithelial defect are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Persistent corneal epithelial defect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Al Shifa Eye Trust Hospital

    RECRUITING

    Rawalpindi, Punjab Province, 46000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.